Indication:
SONIB (Sorafenib Tosylate INN) 200mg is used to treat hepatocellular carcinoma (liver cancer), renal cell carcinoma (kidney cancer), and differentiated thyroid carcinoma (thyroid cancer that doesn’t respond to radioactive iodine treatment.

Pharmacology:
Sorafenib Tosylate inhibits multiple protein kinases involved in tumor cell growth and angiogenesis, effectively hindering tumor progression.

Dosage and Administration:
The standard dosage of SONIB is 400mg taken orally twice daily, with or without food.Tablets should be swallowed whole with water, and dosage adjustments may be made based on individual patient needs.

Interactions:
SONIB can interact with various medications, including other anti-cancer drugs and drugs metabolized by the liver. Patients should disclose all medications to their healthcare provider before starting SONIB.

Side Effects:
Common side effects include diarrhea, fatigue, skin reactions, hypertension, and nausea. Serious effects may include liver problems, bleeding, and cardiac issues.

Precautions and Warnings:
Regular monitoring of liver function, blood pressure, and thyroid function is recommended during SONIB treatment. Caution is advised for patients with cardiac or bleeding disorders. SONIB can harm a fetus and should be avoided during pregnancy, with effective contraception used during treatment. Breastfeeding should also be avoided.

Overdose Effects:
Overdose may result in severe diarrhea, skin reactions, and liver problems. Management typically involves supportive care and monitoring of vital signs.